Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Maurizio Paciaroni, Birsen Ince, Bo Hu...
https://pubmed.ncbi.nlm.nih.gov/31867054/Actively Recruiting
Led by Kafrelsheikh University · Updated on 2025-09-05
900
Participants Needed
1
Research Sites
3 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of combining aspirin with either ticagrelor or clopidogrel in adults aged 18 to 75 who have experienced their first large-vessel minor ischemic stroke or transient ischemic attack TIA. This randomized controlled trial aims to compare a 180 mg loading dose of ticagrelor given within 24 hours of stroke onset to a 300 mg loading dose of clopidogrel, assessing outcomes such as stroke recurrence and bleeding risks. Participants are assigned to one of two groups. The ticagrelor group receives a 180 mg loading dose within 24 hours, followed by 90 mg twice daily from day 2 to day 90, along with a 300 mg aspirin loading dose and a maintenance dose of 75 mg aspirin. The clopidogrel group receives a 300 mg loading dose within 24 hours, then 75 mg once daily from day 2 to day 90, also with aspirin loading and maintenance doses. The study is double-blinded and includes clinical assessments, imaging, and laboratory tests throughout. During the study, participants undergo clinical evaluations including NIH Stroke Scale NIHSS assessments on admission and day 7, and Modified Rankin Scale mRS evaluations after one week and at three months. Imaging such as CT and MRI scans are performed, along with routine lab tests and monitoring for adverse effects. Researchers will measure new stroke rates, drug-related bleeding complications, and other vascular events over 90 days. Safety and treatment effects are closely followed with questionnaires and clinical visits.
CONDITIONS
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
M
mohamed G. Zeinhom, MD
S
sherihan R. ahmed, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kafrelsheikh University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment and informed consent
Duration - 90 days
Participants receive either ticagrelor with aspirin or clopidogrel with aspirin to treat large-vessel minor stroke or TIA.
Visits on admission, day 7, and day 90 including clinical assessments and imaging
Duration - Up to 90 days after treatment start
Participants are followed up to assess stroke recurrence, safety, and functional outcomes.
Face-to-face visits at 1 week and 3 months for follow-up assessments
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maurizio Paciaroni, Birsen Ince, Bo Hu...
https://pubmed.ncbi.nlm.nih.gov/31867054/Dawn M Meyer, Karen C Albright, Teresa A Allison...
https://pubmed.ncbi.nlm.nih.gov/18190818/Kafrelsheikh University
Lead Sponsor